Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Conditions
- Smoldering Plasma Cell Myeloma
Interventions
- BIOLOGICAL: Daratumumab
- DRUG: Dexamethasone
- DRUG: Lenalidomide
- OTHER: Quality-of-Life Assessment
- OTHER: Questionnaire Administration
Sponsor
ECOG-ACRIN Cancer Research Group
Collaborators